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Abstract
Prognostic markers for glioblastoma multiforme (GBM) are important for patient management. Recent advances have
identified prognostic markers for GBMs that use telomerase or the alternative lengthening of telomeres (ALT) mechanism
for telomere maintenance. Approximately 40% of GBMs have no defined telomere maintenance mechanism (NDTMM), with
a mixed survival for affected individuals. This study examined genetic variants in the cyclin-dependent kinase inhibitor 2A
(CDKN2A) gene that encodes the p16
INK4a and p14
ARF tumor suppressors, and the isocitrate dehydrogenase 1 (IDH1) gene as
potential markers of survival for 40 individuals with NDTMM GBMs (telomerase negative and ALT negative by standard
assays), 50 individuals with telomerase, and 17 individuals with ALT positive tumors. The analysis of CDKN2A showed
NDTMM GBMs had an increased minor allele frequency for the C500G (rs11515) polymorphism compared to those with
telomerase and ALT positive GBMs (p=0.002). Patients with the G500 allele had reduced survival that was independent of
age, extent of surgery, and treatment. In the NDTMM group G500 allele carriers had increased loss of CDKN2A gene dosage
compared to C500 homozygotes. An analysis of IDH1 mutations showed the R132H mutation was associated with ALT
positive tumors, and was largely absent in NDTMM and telomerase positive tumors. In the ALT positive tumors cohort, IDH1
mutations were associated with a younger age for the affected individual. In conclusion, the G500 CDKN2A allele was
associated with NDTMM GBMs from older individuals with poorer survival. Mutations in IDH1 were not associated with
NDTMM GBMs, and instead were a marker for ALT positive tumors in younger individuals.
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Introduction
Acquisition of a telomere maintenance mechanism prevents
telomere attrition and is a hallmark of cancer [1,2]. Most tumors
utilize the telomerase enzyme to maintain telomere DNA repeats,
and a minority use an alternative mechanism characterized by
heterogeneous telomere lengths known as alternative lengthening
of telomeres (ALT) [3,4]. In the case of tumors negative for
telomerase and ALT by standard assays (non defined telomere
maintenance mechanism, NDTMM), it is unclear if no telomere
maintenance occurs, if telomerase activity is below the detection
limit of the current assays, or if telomeres are maintained by an
unrecognized mechanism.
In glioblastoma multiforme (GBM) all of the telomere
maintenance scenarios outlined above occur [5]. Individuals with
ALT positive GBMs have an improved prognosis compared to
non-ALT GBMs. Within the ALT positive GBM group the
prognosis is better for those individuals with mutations in the
tumor protein p53 (TP53) gene, and mutations in the isocitrate
dehydrogenase 1 gene [5,6,7,8]. In telomerase positive tumors
TP53 mutations are a marker for individuals with a poorer
prognosis [5,7,8]. To date no prognostic markers have been
identified for the approximately 40% of patients whose GBMs are
without a currently defined telomere maintenance mechanism.
Other molecular characteristics of GBMs include loss of the
cyclin-dependent kinase inhibitor 2A (CDKN2A) that encodes two
proteins p16
INK4a and p14
ARF [9,10,11]. The most frequent
polymorphism in CDKN2A, a substitution in the 39 UTR of a
cytosine for a guanine base at cDNA nucleotide 500 (numbered
from the p16
INK4a initiation codon, rs11515), is associated with
different cancer types. The G500 allele had an increased
frequency in melanoma families, and in psoriasis patients with
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26737squamous cell carcinoma [12,13,14]. The G500 allele predicted a
shorter progression time from primary to metastatic melanoma, a
reduced tumor free survival period in individuals with bladder
carcinoma, and was associated with loss of p16
INK4a expression in
sporadic colorectal cancer [15,16,17]. Functional evaluation of the
C500G polymorphism is in its infancy. This polymorphism is
predicted to affect the micro RNA (MiR) 601 binding, and the
G500 allele is associated with increased CDKN2A expression
[18,19]. The G500 allele is also associated with reduced cyclin
dependent inhibitor 2B (CDKN2B) expression; a gene in close
proximity to CDKN2A on chromosome 9p21 and encodes the
tumor suppressor p15
INK4B [19].
Due to the potential importance for the CDKN2A C500G
polymorphism and IDH1 mutations in GBM, the current study
investigated the C and G 500 allele frequencies in genomic DNA,
and IDH1 mutations in tumor DNA from 107 individuals with
telomerase, ALT, and NDTMM GBMs. The G500 allele was
associated with NDTMM tumors and was further evaluated as a
marker for reduced patient survival, and increased loss of CDKN2A
gene dosage in tumors.
Results
One hundred and seven GBM tumors were obtained at
neurosurgical units within New Zealand. Seventeen tumors
(16%) were ALT positive by standard techniques i.e. long and
heterogeneous telomere lengths by TRF length analysis, the
presence of large aggregates of the promyelocytic leukemia (PML)
protein and telomere DNA called ALT-associated promyelocytic
leukemia (PML) bodies (APBs) in .0.5% of tumor cells, and very
low or no telomerase activity in tumor protein lysates by the
TRAP assay [3,8]. Fifty tumors (47%) were telomerase positive by
TRAP analysis. Forty tumors (37%) were classified as telomerase
activity negative based on the standard TRAP assay criteria, and
negative for ALT by the absence of long heterogeneous telomeres
by TRF analysis [5,8]. Henceforth, these tumors are referred to as
NDTMM. The demographic data for the ALT, NDTMM, and
telomerase positive tumor groups are listed in Table 1.
The G500 allele is associated with GBMs with no defined
telomere maintenance mechanism
Individuals in each GBM telomere maintenance subgroup were
genotyped for the C500G polymorphism in the 39 CDKN2A UTR
(rs11515). The C500G genotypes are given in Table 2. In the
NDTMM tumor group 19 individuals were heterozygous and two
were homozygous for the G500 allele (allele frequency 0.29), and
19 were homozygous for the C500 allele. In the telomerase
positive tumor group 12 individuals were heterozygous for G500
(allele frequency 0.12), and 38 were homozygous for the C500
allele. In the ALT positive tumor group three individuals were
heterozygous for G500 (allele frequency 0.09), and 14 were
homozygous for the C500 allele. The G500 allele frequency was
significantly higher in the NDTMM compared to the telomerase
(p=0.007) and the ALT (p=0.03) tumor group (p=0.002,
NDTMM versus telomerase and ALT positive GBMs combined).
The G500 allele was also genotyped in 150 control individuals
selected from the general population (Table 1). In the general
population the G500 allele frequency was 0.13, significantly lower
compared to the NDTMM tumor group (p=0.001), but not
significantly different to the telomerase positive GBM group.
All individuals with the G500 allele were homozygous for the
major allele at two other polymorphic sites in close proximity
(C540T and C547G). No CDKN2A mutations were identified in
G500 heterozygotes as evident by dHPLC and sequence analysis
of all CDKN2A exons and exon/intron boundaries in amplicons of
Table 1. Demographic Characteristics of GBM Patients.
Characteristic ALT+ NDTMM TEL+ Significance between groups
Age years (25
th–75
th percentile) 40 (34–51) 65 (51–71) 61 (48–68) *p,0.001
Gender n (%) ns
Male 10 (59%) 27 (54%) 28(56%)
Female 7 (41%) 23 (46%) 22 (44%)
Treatment n (%) 16 39 44
Surgery only 3 (19%) 6 (15%) 6 (13%) ns
Surgery +RT 7 (44%) 18 (46%) 21 (47%) ns
Surgery +RT + CT 6 (38%) 14 (36%) (21 (47%) ns
Extent of surgery ns
Biopsy 4 (24%) 9 (22%) 12 (24%)
Debulking 13 (76%) 31 (78%) 38 (76%)
*The significant difference for both the ALT+ versus NDTMM, and the ALT+ versus TEL+ GBM comparison. RT, radiotherapy; CT, chemotherapy.
doi:10.1371/journal.pone.0026737.t001
Table 2. The G500 allele is more frequent in GBMs without a
definitive telomere maintenance mechanism.
Telomere Maintenance
Mechanism N G500 allele frequency
Non telomerase-ALT 40 0.29 (19 C/G, 2 G/G, 19 C/C)**
Telomerase 50 0.12 (12 C/G, 38C/C)
ALT 17 0.09 (3 C/G, 14 C/C)
Non tumor cohort 150 0.13 (32 C/G, 3 G/G, 115 C/C)
n, number of individuals; non-tumor cohort, controls selected from the same
general population; non telomerase-ALT, GBM negative for telomerase activity
and ALT. The number of individuals with each genotype is given in parentheses;
**, p=0.007, non telomerase-ALT versus telomerase positive, Odds Ratio 0.333,
95% CI 0.156–0.732; p=0.002, non telomerase-ALT versus telomerase and ALT
combined, Odds Ratio, 0.312, 95% CI 0.152–0.643; p=0.001, non telomerase-
ALT versus the non-tumor cohort selected from the same general population,
Odds Ratio 0.365, 95% CI 0.2–0.67. All comparisons were tested using the
Fisher’s exact test p,0.05 was taken as a significant difference.
doi:10.1371/journal.pone.0026737.t002
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with telomerase, 1 with an ALT, and 5 with NDTMM tumors)
were heterozygous for the G442A polymorphism that substitutes
an adenine for a tyrosine amino acid at amino acid residue 148 in
p16
INK4a.
In summary, in GBM the G500 allele and no other CDKN2A
sequence variant examined was associated with an increased
frequency in the NDTMM group. In the telomerase GBM group
the G500 allele frequency was not significantly different to the
control population selected with the same ethnicity, and age and
sex matched to the GBM cohort.
The G500 allele is associated with poorer survival in
individuals with GBMs with no defined telomere
maintenance mechanism
Cox proportional hazards regression analysis was performed to
test whether the GC and CC C500G genotypes in the NDTMM
and telomerase positive groups were independently associated with
survival. Variables included in the analysis were age, gender,
treatment, and extent of surgery (Table 3). The C500G SNP was
significantly associated with survival with the adjusted ratio for
survival (p=0.029, variable 1=CC, Hazard ratio 0.197, 95% CI
0.046–0.844). Other variables independently associated with
altered survival were age (p=0.037, variable age in years, hazard
ratio 1.021, 95% CI 1.001–1.041) and chemotherapy treatment
(p=0.002, variable chemotherapy yes=1, hazard ratio 0.392,
95% CI 0.220–0.699).
In the NDTMM tumor group survival data was available for all
40 individuals. Individuals heterozygous for the G500 allele had a
median survival time of 3 months following the initial tumor
diagnosis, compared to 8 months for individuals homozygous for
the C500 allele (Figure 1A). The two individuals homozygous for
the G500 allele had survival times of 1 and 2 months post tumor
diagnosis, respectively. The median age for G500 heterozygotes
with a NDTMM GBM was 66 (60–75, 25
th to the 75
th percentile),
which was higher compared to a median age of 58 for C500
homozygotes (41–70, 25
th to the 75
th percentile), p=0.04 (two
tailed unpaired t test with Welch’s correction, 95% CI).
In the telomerase positive tumor group survival data was
available for 44 of 50 individuals. Individuals heterozygous for the
G500 allele had a median survival time of 4.9 months following
the initial tumor diagnosis compared to median survival time of 6
months for CC homozygotes (Figure 1B).
The G500 allele is associated with p16
INK4a gene loss in
GBMs with no defined telomere maintenance
mechanism
To test if the reduced survival associated with the G500 allele in
the NDTMM GBM cohort was attributed to a greater loss of
homozygosity or heterozygosity for p16
INK4a or p14
ARF, multiplex
PCR was used to estimate the gene dosage of exon 1a (p16
INK2A)
and exon 1b (p14
ARF) relative to an internal b-globin gene
fragment [20]. In the NDTMM group, 15 out of 19 G500
heterozygotes had exon 1a and exon 1b loss of homozygosity or
loss of heterozygosity, and 4 retained exon 1a and exon 1b
homozygosity. In C500 homozygotes, 7 individuals had exon 1a
and exon 1b loss of homozygosity or loss of heterozygosity, and 12
retained exon 1a and exon 1b homozygosity. The increased
Table 3. Cox Proportional Hazards Model for Factors
Affecting Survival.
Variable p HR (95% CI)
Age (years) 0.037 1.021 (1.001–1.041)
Gender 0.469 1.215 (0.717–2.058)
Tumor resection 0.333 0.735 (0.395–1.371)
Surgery + Radiotherapy 0.393 0.724 (0.346–1.517)
Surgery + Radiotherapy + Chemotherapy 0.002 0.392 (0.220–0.699)
C500G SNP (CC) 0.027 0.197 (0.046–0.844)
NDTMM 0.451 0.558 (0.123–2.541)
p16
INK4A loss 0.224 0.419 (0.1–1.755)
HR, Hazard ratio; 95% CI, 95% Hazard ratio confidence limits.
doi:10.1371/journal.pone.0026737.t003
Figure 1. Patient survival with the G500 allele compared to
C500 homozygotes for individuals with NDTMM and telome-
rase positive GBMs. A. Kaplan-Meier survival analysis post tumor
diagnosis for individuals with GBMs with no defined telomere
maintenance mechanism (NDTMM). Survival data was available for all
38 individuals (the G500 homozygotes were excluded from the
analysis). B. Kaplan-Meier survival analysis post tumor diagnosis for
individuals with telomerase positive GBMs. Survival data was available
for 44 individuals. Individuals genotyped as heterozygote for the C500G
polymorphism (G500) in the 39 CDKN2A UTR were associated with
reduced survival compared to C500 homozygotes (C500) using a multi-
variant Cox proportional hazards regression analysis (Table 3).
doi:10.1371/journal.pone.0026737.g001
Risk Factors for Glioblastoma Multiforme
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26737frequency of exon 1a and of exon 1b loss in G500 carriers
compared to C500 homozygotes was significant (p=0.02).
In the NDTMM group, individuals heterozygous for G500 that
had loss of exon 1a and 1b gene dosage had a median survival of 4
months, which was not significantly different to G500 heterozyotes
that retained exon 1a and 1b homozygosity (median survival 3
months, Figure 2). However, the few individuals that retained gene
dosage limit this comparison. Individuals homozygous for the
C500 allele that had loss of exon 1a and 1b gene dosage had a
median survival of 2.5 months, which was significantly reduced
compared to those that retained exon 1a and 1b homozygosity
(median survival 9 months, p=0.016 hazard ratio 3.3, Figure 2).
Cox proportional hazards regression analysis was performed to
test whether loss of p16
INK4a was an independent variable
associated with survival. Loss of p16
INK4a was not associated
(p=0.419) with altered survival when adjusted for other variables
(Table 3).
In summary, in NDTMM GBMs with the G500 allele had
increased loss of exon 1a and 1b. Improved survival was found
with NDTMM GBMs homozygote for C500 and no loss of exon
1a and 1b; however, loss of p16
INK4a was not and independently
associated with survival when multiple variables were analyzed.
To verify that the NDTMM GBMs had lost the p16
INK4a gene,
tumor sections were analyzed using a fluorescent in situ
hybridization [21] and immunohistochemistry assays. For the
FISH analysis, sections were incubated with a probe to the
p16
INK4a locus and a control probe to chromosome 9 labeled with a
different fluorophore (P16 Deletion Probe, Cytocell Ltd, Cam-
bridge UK). The 20 tumor sections selected included ten from
G500 heterozygotes typed with loss of p16
INK4a gene dosage using
the multiplex PCR analysis and ten tumors from C500
homozygotes typed with no loss in p16
INK4a gene dosage by
multiplex PCR analysis. All tumors from C500 homozygotes had 2
red and 2 green signals in cellular nuclei, a result consistent with
no loss in p16
INK4a gene dosage (data not shown). Seven tumors
from G500 heterozygotes had 2 green signals and no red signals
consistent with a loss of both p16
INK4a alleles (data not shown).
Three tumors from G500 heterozygotes had 2 green signals and 1
red signal consistent with a loss of one p16
INK4a allele. The results
from the FISH analysis confirmed those obtained using PCR.
For the immunohistochemistry analysis, sections were incubated
with an antibody to p16
INK4a. The 20 tumor sections selected were
those used for the FISH analysis described above. All tumors from
C500 homozygotes had p16
INK4a positive cells (Figure 3A), a result
consistent with p16
INK4a expression. Seven tumors from G500
heterozygotes had no p16
INK4a positive cells, consistent with loss of
both p16
INK4a alleles (Figure 3B).
In the telomerase positive and ALT positive groups no
significant difference occurred for exon 1a and 1b gene dosage
between G500 heterozygotes and C500 homozygotes using the
multiplex PCR. In telomerase positive tumors, 9 out of 12 tumors
from G500 heterozygotes had loss of homozygosity or loss of
heterozygosity for exon 1a and 1b, 1 had lost exon 1a but retained
exon 1b gene dosage, and 2 retained both exon 1a and exon 1b
Figure 2. The improved prognosis for C500 homozygotes is
associated with retention of p16
INK4a and p14
ARF. Kaplan-Meier
survival analysis from Figure 1A with individuals with GBMs with no
defined telomere maintenance mechanism further divided on exon 1a
(p16
INK4A) gene dosage. Individuals homozygous for C500 were divided
into those that had loss of homozygosity or loss of heterozygosity
(C500 p16 loss) and those that retained exon 1a homozygosity (C500
p16 wt) by multiplex PCR of tumor DNA. The same division was made
for G500 heterozygotes (G500 p16 loss and G500 p16 wt). The C500 p16
loss group had a significantly poorer survival to the C500 p16 wt group
(p=0.016, log-rank test with 95% CI). No difference in survival occurred
for the G500 p16 loss and G500 p16 wt comparison. All associations for
p16
INK4a pertained to p14
ARF due to identical exon 1a and exon 1b gene
dosage.
doi:10.1371/journal.pone.0026737.g002
Figure 3. Tumors with the non defined telomere maintenance
mechanism with both p16
INK4a alleles produce p16
INK4a. All
tumors used to confirm the presence or losses of p16
INK4A gene dosage
by fluorescent in situ hybridization [21] were analyzed by immunohis-
tochemistry for the p16
INK4A protein. A. Photomicrographs to illustrate
tumor cells positive for p16
INK4A in a GBM typed with both p16
INK4A
alleles by FISH. B. Photomicrographs to illustrate tumor cells negative
for p16
INK4A in a GBM typed with loss of both p16
INK4A alleles by FISH.
DAB positive cells were detected by light microscopy at 4006
magnification, scale bars are included.
doi:10.1371/journal.pone.0026737.g003
Risk Factors for Glioblastoma Multiforme
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26737gene dosage. In C500 homozygotes with telomerase positive
tumors, 20 out of 38 tumors had loss of homozygosity or loss of
heterozygosity for exon 1a and 1b, 2 had lost exon 1a but retained
exon 1b gene dosage, 2 had lost exon 1b but retained exon 1a
gene dosage, and 9 retained both exon 1a and exon 1b gene
dosage. In ALT positive GBMs, 3 out of 3 tumors from G500
heterozygotes had loss of heterozygosity for exon 1a and 1b.I n
C500 homozygotes with ALT positive tumors, 9 out of 14 tumors
had loss of homozygosity or loss of heterozygosity for exon 1a and
1b, and 5 retained both exon 1a and exon 1b gene dosage.
Isocitrate dehydrogenase 1 mutations are associated
with ALT positive GBMs
Tumor DNA from all GBMs was used as the template in PCR
reactions that amplified all exons of IDH1 and exon 4 of IDH2.
Sequence analysis was used to identify missense mutations. Twelve
GBMs were heterozygote for missense mutations in IDH1. Eleven
individuals carried the R132H mutation; the most frequent IDH1
missense mutation documented for GBM [22,23]. One individual
carried the R132L mutation also reported for GBM [24]. Ten
tumors with IDH1 missense mutations were ALT positive, thus
IDH1 mutations were present in 59% (10 of 17) of the ALT cohort
and 11% of total GBMs. Mutations in IDH1 were present in one
telomerase positive (2%) and one NDTMM (2.5%) tumors. The
frequency of IDH1 mutations in ALT was significant when
compared to both telomerase and NDTMM tumors (Pearson’s chi
square test p,0.001 for both the comparison of ALT with
telomerase, and ALT with NDMM tumors). All individuals with
R132H mutations were under 45 years of age, with one exception
the individual with the telomerase positive tumor. In the ALT
positive tumor cohort, the younger age of individuals with IDH1
mutations was significant compared with those without IDH1
mutations (median age 36 versus 52, 25
th to the 75
th percentile 26–
40.5 versus 48–61, p,0.001). For IDH2 mutations, one mutation
was found. The D177A, amino acid residue substitution occurred
in a NDTMM GBM.
In summary, the majority of ALT positive tumors contained
IDH1 mutations. In NDTMM and telomerase positive GBMs,
IDH1 mutations were rare.
Discussion
Currently there is no prognostic marker for GBM tumors
without a defined telomere maintenance mechanism. The G500
CDKN2A allele may be an important biomarker for NDTMM
GBMs identifying individuals with a poorer prognosis. The
C500G genotype was associated with survival independently of
age and treatment, which are other factors associated with GBM
patient survival [6,21,25,26].
It is unknown why a considerable portion of GBMs have no
currently defined telomere maintenance mechanism. Most tumor
types documented without telomerase activity or ALT are low-
grade tumors such as grade 1 astrocytomas and papillary thyroid
carcinomas [8,27]. With few exceptions telomerase activity is
measured using the TRAP assay, which is sensitive for detecting
telomerase activity in 0.01% of telomerase positive cells in a mixed
population [5,7,28]. Inhibitors of the TRAP assay in tumor cell
lysates may produce false negative results [29]. In this study,
measuring telomerase activity using at least four different dilutions
of each lysate reduced this limitation of the TRAP assay inhibitors.
All tumors classified as ALT negative had mean TRF lengths
below 13 kbp and did not show a heterogeneous TRF profile.
Non-defined telomere maintenance mechanism tumors had fewer
TP53 mutations compared to ALT positive tumors (unpublished
observations). Moreover, the different G500 allele frequency, the
absence of IDH1 mutations, and the different effect of mutant
TP53 on survival (also replicated in this GBM cohort, data not
shown) on survival mitigates against these ‘‘None’’ GBMs being
miss-classified as telomerase or ALT tumors [7]. Our data suggest
that the NDTMM tumors are a distinctive subgroup of GBMs.
The G500 allele was associated with an increased age in
heterozygotes compared to C500 homozygotes in the NDTMM
group, therefore the age and composition of GBM cohorts may
affect the NDTMM tumors present.
The G500 allele as a risk factor for cancer has been most
extensively characterized for melanoma [12,13,30]. The G500
allele had an increased frequency in patients from families with a
high risk of melanoma [12]. How the G500 allele affects cancer
risk is unknown, but may lead to loss of p16
INK4a and p14
ARF
expression [16][15]. Deletion of CDKN2A is associated with poor
tumor outcome in patients and mice [31,32,33]. The mechanism
by which the G500 allele leads to a loss of exon 1a and exon 1b in
NDTMM GBMs is unclear and not immediately intuitive, and
requires further investigation. One could predict that a C500G
base substitution in a 39 UTR could alter the stability of the
p16
INK4a and p14
ARF transcripts, which may give a greater selection
pressure for inactivation by a later DNA deletion [34]. MiR-601
binding to CDKN2A was predicted to be affected by the C500G
polymorphism [18].
The G500 allele was not associated with another sequence
variant in the CDKN2A coding region or the 39 UTR of CDKN2A
region analyzed. The C500G alleles may affect expression of other
genes in close proximity to CDKN2A. Both CDKN2B and the non-
coding RNA designated ANRIL are included with CDKN2A in the
susceptibility locus associated with glioma and other diseases
[35,36,37,38]. According to Cunnington et al. (2010), the G500
allele reduced CDKN2B and no effect on ANRIL expression [19].
The causative variant may be in linkage disequilibrium with the
G500 allele and in a region on chromosome 9 not analyzed in this
study.
Homozygotes for the C500 allele with loss of exon 1a and exon
1b gene dosage had a poorer survival compared to those that had
retained exon 1a and exon 1b, consistent with an association
between loss of p16
INK4a and p14
ARF function and poorer survival.
Interestingly, this was not the case for G500 heterozygotes, as
those that had loss of exon 1a and exon 1b gene dosage had no
difference in survival compared to those that retained exon 1a and
exon 1b. One explanation for this discrepancy is that the G500
allele may lead to loss of p16
INK4a and p14
ARF transcripts initially,
followed by loss of exon 1a and exon 1b DNA at a latter stage of
tumor development. The poorer survival associated with the G500
allele may be attributed in part to an increased age at initial tumor
diagnosis for G500 heterozygotes [39]. Tumor surveillance and
genome protection may be compromised by age leading to a more
rapidly fatal tumor. Although the C500 allele is associated with
improved prognosis in NDTMM GBMs, its association with a
younger age is indicative that it could be considered a risk allele for
this GBM type. The C500 allele was the risk factor for Alzheimer’s
disease [40]. A greater understanding of the function of each allele
is required to ascertain how the base change leads to increased
disease susceptibility.
The NDTMM GBMs were not associated with IDH1 mu-
tations, a marker for improved prognosis in ALT positive tumors
[6]. Consistent with another report, IDH1 mutations in the
current study were associated with ALT positive GBMs. The
percentage of ALT positive GBMs (59%) in the current study was
higher than that previous reported (18.8%) [6]. This difference
could be attributed to the different techniques used to identify
Risk Factors for Glioblastoma Multiforme
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in the previous report) or a difference in the age of the ALT
positive GBM cohort (median age 36 versus 50 in the previous
report). GBMs with IDH1 mutations are associated with reduced
age for affected individuals, and in our ALT positive tumor cohort
all individuals with IDH1 mutations were aged under 45 [23,41].
Mutations in IDH1 are thought to occur early in tumorigenesis,
with recent evidence suggesting IDH1 mutations may have tumor
promoting functions [42,43]. In glioma IDH1 mutations are
associated with a CpG methylator phenotype [44]. In acute
myeloid leukemia IDH1 mutations have been proposed to increase
global hypermethylation by blocking the function of the tet
oncogene family member 2 function [45]. The molecular
mechanism by which IDH1 mutations and ALT are associated
in Glioma remains to be understood.
New treatments targeting telomerase positive tumors are being
developed [46]. If successful, an analysis of tumor telomere
maintenance mechanisms may be important to identify individuals
that would benefit from telomerase inhibitors. Other treatment
approaches may be required for those with ALT positive and
tumors with no defined telomere maintenance mechanism.
Conclusion
The CDKN2A G500 allele in the 39 UTR was more frequent in
patients with tumors that have no defined telomere maintenance
mechanism and was a prognostic marker for poorer survival. The
increased incidence of the G500 allele and the absence of IDH1
mutations provide justification for the NDTMM GBMs being a
molecularly distinct subgroup of tumor. Further investigation is
required to understand the function of the G500 allele in altered
cancer risk. In younger GBM patients with ALT positive tumors,
IDH1 mutations predominate. Therefore the molecular signature
of telomere maintenance mechanisms may provide additional
prognostic information for GBM patients in addition to that for
age and treatment received.
Materials and Methods
Ethics Statement
The study had ethical approval from the Multi-region Ethics
and the Upper South Regional Ethics committees in New
Zealand, and written individual informed consent was obtained.
Tumor Collection
The inclusion criterion for the study was a diagnosis of a GBM
tumor. One hundred and seven tumors with both paraffin-
embedded and frozen tissue available were analyzed. All tumors
were collected in New Zealand, and all were debulking samples.
Consultant pathologists performed the histopathological tumor
diagnoses. All individuals were of New Zealand European
ethnicity.
Telomere Maintenance Mechanism Analyzes
Telomerase activity was measured in tumor lysates using the
Telomeric Repeat Amplification Protocol (TRAP) method. The
TeloTAGGG Telomerase PCR ELISA Plus kit (Roche Applied
Science, Mannheim, Germany) was used according to the
manufacturer’s instructions. For identification of ALT positive
tumors, measurement of telomere length was made by the
terminal restriction fragment (TRF) assay using tumor lysates.
The TeloTAGGG Telomere Length Assay Kit (Roche Applied
Science, Mannheim, Germany) was used according to the
manufacturer’s instructions. The criteria for ALT by TRF
length was that previously described [8]: mean TRF length
.16 kbp, with a wide range in TRF lengths (typically ,3t o
.50 kbp). Determination of ALT was also made by measure-
ment APBs. Co-localized bodies of PML and telomere DNA, in
cellular nuclei, were performed on sectioned paraffin embedded
tumors and determined according to the APB assay criteria
described previously [8]. Cellular nuclei were stained using
DAPI. Cells were imaged using confocal microscopy (Zeiss
LSM510; Carl Zeiss, NY USA), and images analyzed by Zeiss
LSM Image Examiner software version 3.2.0.115 (Carl Zeiss,
NY USA).
Genetic analyses of CDKN2A
C500G polymorphism genotyping. To genotype the
C500G (rs11515) polymorphism [47], a 435 bp region inclusive
of C500G, and two other single nucleotide polymorphisms in close
proximity (C540T rs3088440 and C547G rs79294022) were
amplified from DNA extracted from blood leukocytes followed
by sequencing. The PCR reaction used a sense primer in intron 2
(59-GTGCCACACATCTTTGACCTCAG-39) and an anti-sense
prime in the 39 UTR (59-TGCTTGTCATGAAGTCGACAG-
CT-39). The C500G alleles were genotyped in 150 blood leukocyte
extracted DNA samples from individuals randomly selected from
the general New Zealand population of European ancestry.
CDKN2A coding region amplification. All exons of
CDKN2A were amplified by PCR using blood leukocyte and
tumor extracted DNA as the template. The following sets of
primers were used to amplify exon 1a (sense 59-ACCGGAG-
GAAGAAAGAGGAG-39, antisense 59-AGTCGCCCGCCATC-
CCCT-39) and 1b (sense 59-CGCTCAGGGAAGGCGGGTGC-
GCG-39, antisense 59-CCTAGCCTGGGCTAGAGACG-39)
[48]. Primers sequences for amplification of exon 2 and 3 were
those previously described [49]. All PCR products were screened
for sequence variants by denaturing HPLC (d-HPLC) using the
WAVE system (Transgenomic, NE, USA), and sequenced
(ABI3730 DNA Analyzer, AB Applied Biosystems, CA, USA) if
aberrant dHPLC profiles indicative of sequence variation
presented. If sequence variants were not predicted, PCR
products were mixed with CDKN2A wild-type DNA (1:1) and re-
analyzed by dHPLC to allow non-heterozygous sequence variants
to be detected.
CDKN2A gene dosage using multiplex PCR. Multiplex
PCR as previously described for astrocytomas, was used to assay
the gene dosage of CDKN2A exon 1a (p16
INK4A) and exon 1b
(p14
ARF) using tumor extracted DNA [20]. The multiplex PCR
designed to amplify exon 1a and that for exon 1b amplified part of
the b-Globin gene as an internal control. PCR product intensities
were analyzed by gel electrophoresis and used Bio-Rad Quantity
One (Bio-Rad Laboratories, CA, USA) and Syngene GeneTools
image software (Syngene, Cambridge, UK).
p16
INK4a gene dosage using fluorescent in situ hy-
bridization. In situ hybridization was used to confirm the
p16
INK4a gene dosage results obtained from the multiplex PCR
method, and measured p16
INK4a gene dosage in 20 NDTMM
GBM paraffin embedded tumor sections using the P16 Detection
Probe (Cytocell Aquarius, Cambridge, UK) and the control
chromosome 9 probe deletion probe (D9Z3 Cytocell Aquarius).
The in situ hybridization protocol was based on that used in the
laboratory for FISH analysis of telomeric DNA [50]. Cellular
nuclei were stained using DAPI. Cells were imaged using
microscopy (Zeiss LSM510; Carl Zeiss, NY USA), and analyzed
by Zeiss LSM Image Examiner software version 3.2.0.115 (Carl
Zeiss) to identify tumor cell nuclei with 1, 2, or no red dots, and
two green dots.
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To identify tumors with IDH1 mutations all exons of the IDH1
gene were amplified from tumor extracted DNA and sequenced.
With the exception of the PCR reaction designed to amplify exon
4, which used the following set of primers, sense 59-ATGCCAT-
CACTGCAGTTGTAGG-39 and antisense 59-CCTTGCTT-
AATGGGTGTAGAT-39, all primers used were those described
previously [9]. The analysis of IDH2 mutations was limited to an
analysis of exon 4, which was amplified from tumor DNA using





INK4a epitope was detected using an anti-mouse p16
INK4a
monoclonal antibody (ab454210, Abcam, Cambridge. MA), and
detection of the enzyme linked conjugated system (ENVision Dual
Link, Dako, Glostrup, Denmark) used DAB. Detection of DAB
positive cells used a Leica DM2000 light microscope at 4006
magnification and Leica Version 3.5.0 Application Suite software
(Leica Microsystems, Wetzlar, Germany).
Survival and Statistical Analyses
The primary end point was overall survival. Cox proportional
hazards regression analysis was performed to assess the GC and
CC G500C genotypes as a prognostic marker for survival and was
adjusted for other variables age (years), gender, tumor resection
(biopsy only, debulking), and treatment (radiotherapy yes or no,
chemotherapy yes or no), loss of p16
INK4a. The analysis was made
using the PHREG Procedure SAS System (Local, WIN_PRO,
SAS Institute, Cary, NC).The frequency of the G500 allele was
compared between GBMs with different telomere maintenance
mechanisms using the Fisher’s exact test and GraphPad Prism
software (GraphPad Software, CA, USA). In the NDTMM and
telomerase GBM groups the age at brain tumor diagnosis was
compared between G500 heterozygotes and C500 homozygotes,
and used the unpaired Student’s t test with 95% CI and Welch’s
correction to compensate for unequal variance. In the NDTMM
and telomerase GBM groups, the loss of homozygosity or the loss
of heterozygosity of exon 1a or exon 1b was compared to tumors
that retained exon 1a or exon 1b homozygosity using the Fisher’s
exact test and GraphPad Prism software (GraphPad). The
frequency of missense mutations in IDH1 was compared between
GBMs with different telomere maintenance mechanisms using the
Pearson’s chi square test and SHEsis software [51]. A p,0.05 was
taken as a significant difference. The association between age,
telomere maintenance mechanism, and IDH1 mutation status was
analysed using the analysis of variance test and used GraphPad
Prism software (dependent variable being age).
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